Piper Sandler Maintains Overweight on CytomX Therapeutics, Raises Price Target to $12

Benzinga Newsdesk www.benzinga.com Positive 82.1%

Neg 0% Neu 0% Pos 82.1%

Piper Sandler analyst Joseph Catanzaro maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $10 to $12.